Fibroblast growth factor receptors (FGFRs) are an emerging target for directed cancer therapy. The aim of this research proposal is to develop a new conjugate aimed at FGFR-expressing cancer cells, based on FGFR-binding peptibody conjugated with a potent cytotoxic drug, monomethylauristatin E (MMAE). New peptides with FGFR-binding properties will be identified within the project and used to construct peptibodies, a promising alternative to monoclonal antibodies. Peptibodies will be then conjugated with MMAE, a cytotoxic drug well-studied for clinical applications, and used as selective delivery vehicles targeting FGFR-expressing cancer cells. These peptibody-drug conjugates May serve as a basis for development of therapy for tumours relying on overexpressed or malfunctioning FGFRs.